Developing a
first-in-class
oral peptide pipeline

While biologic therapies have delivered meaningful efficacy, their injectable administration, safety considerations, and treatment burden often limit long-term adherence and delay initiation. These challenges are especially pronounced in patients with mild to moderate disease, who may be reluctant to start injectable therapies or are not considered appropriate candidates under current treatment paradigms. As a result, a substantial patient population remains underserved, leading to ongoing disease activity and diminished quality of life.

Our proprietary de novo discovery platform enables the design of oral peptides optimized for stability, permeability, and target engagement. This allows us to pursue clinically validated targets while reimagining them as oral therapies suitable for broader patient populations. By moving beyond injection-only paradigms, we aim to expand access to targeted therapies and improve long-term disease control.